41.20
price down icon5.32%   -2.305
 
loading
Veracyte Inc stock is traded at $41.20, with a volume of 423.02K. It is down -5.32% in the last 24 hours and down -3.07% over the past month.
See More
Previous Close:
$43.50
Open:
$43.35
24h Volume:
423.02K
Relative Volume:
0.56
Market Cap:
$3.29B
Revenue:
$399.58M
Net Income/Loss:
$-54.04M
P/E Ratio:
-54.93
EPS:
-0.75
Net Cash Flow:
$40.13M
1W Performance:
-9.45%
1M Performance:
-3.07%
6M Performance:
+52.25%
1Y Performance:
+69.06%
1-Day Range:
Value
$40.46
$43.50
1-Week Range:
Value
$40.46
$46.50
52-Week Range:
Value
$18.61
$47.32

Veracyte Inc Stock (VCYT) Company Profile

Name
Name
Veracyte Inc
Name
Phone
(650) 243-6300
Name
Address
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Name
Employee
0
Name
Twitter
@veracyte
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
VCYT's Discussions on Twitter

Compare VCYT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Diagnostics & Research icon
VCYT
Veracyte Inc
41.20 3.29B 399.58M -54.04M 40.13M -0.75
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
569.14 219.06B 42.88B 6.34B 7.27B 16.53
Diagnostics & Research icon
DHR
Danaher Corp
207.13 151.02B 23.88B 3.90B 5.30B 5.28
Diagnostics & Research icon
A
Agilent Technologies Inc
145.30 42.12B 6.51B 1.29B 1.37B 4.42
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
458.15 37.71B 3.84B 866.24M 792.60M 10.37
Diagnostics & Research icon
IQV
Iqvia Holdings Inc
207.46 36.97B 15.32B 1.41B 1.96B 7.62

Veracyte Inc Stock (VCYT) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-05-24 Downgrade Goldman Buy → Neutral
Nov-15-24 Initiated Wolfe Research Outperform
Oct-16-24 Initiated UBS Buy
Oct-10-24 Initiated Guggenheim Buy
Feb-23-24 Reiterated Needham Buy
Jan-18-23 Downgrade Raymond James Outperform → Mkt Perform
Jan-05-23 Initiated Scotiabank Sector Outperform
Jan-07-22 Initiated Stephens Overweight
Nov-18-21 Resumed Goldman Buy
Jun-15-21 Initiated Raymond James Outperform
Feb-18-21 Resumed Needham Buy
Jan-28-21 Initiated Truist Buy
Nov-10-20 Initiated KeyBanc Capital Markets Sector Weight
Sep-09-20 Initiated Morgan Stanley Underweight
Jul-31-19 Initiated Lake Street Buy
Jul-02-19 Initiated Needham Buy
Nov-29-18 Downgrade Janney Buy → Neutral
Oct-31-18 Upgrade Janney Neutral → Buy
Nov-07-17 Downgrade Janney Buy → Neutral
Nov-07-17 Downgrade Piper Jaffray Overweight → Neutral
Aug-31-17 Resumed BTIG Research Buy
Nov-14-16 Resumed Leerink Partners Outperform
Dec-18-15 Initiated Cantor Fitzgerald Buy
Jun-11-15 Reiterated Leerink Partners Outperform
Nov-26-13 Initiated William Blair Outperform
View All

Veracyte Inc Stock (VCYT) Latest News

pulisher
Feb 06, 2025

Veracyte, Inc. (NASDAQ:VCYT) CFO Rebecca Chambers Sells 527 Shares - MarketBeat

Feb 06, 2025
pulisher
Feb 06, 2025

Veracyte CFO Rebecca Chambers sells $23,108 in stock By Investing.com - Investing.com Australia

Feb 06, 2025
pulisher
Feb 06, 2025

Jennison Associates LLC Acquires 448,251 Shares of Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat

Feb 06, 2025
pulisher
Feb 06, 2025

Insider Sell: Rebecca Chambers Sells Shares of Veracyte Inc (VCY - GuruFocus.com

Feb 06, 2025
pulisher
Feb 05, 2025

Veracyte CFO Rebecca Chambers sells $23,108 in stock - MSN

Feb 05, 2025
pulisher
Feb 05, 2025

New Study Shows Veracyte’s Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer - BioSpace

Feb 05, 2025
pulisher
Feb 05, 2025

Clinical Study: Revolutionary Bladder Cancer Test Predicts Disease Progression with 33% Higher Accuracy - StockTitan

Feb 05, 2025
pulisher
Feb 04, 2025

Cancer Diagnostics Leader Veracyte Schedules Critical Year-End Financial Results - StockTitan

Feb 04, 2025
pulisher
Feb 04, 2025

Veracyte (NASDAQ:VCYT) Sets New 52-Week High After Analyst Upgrade - MarketBeat

Feb 04, 2025
pulisher
Feb 03, 2025

6,621 Shares in Veracyte, Inc. (NASDAQ:VCYT) Purchased by Baader Bank Aktiengesellschaft - MarketBeat

Feb 03, 2025
pulisher
Feb 01, 2025

Veracyte (NASDAQ:VCYT) Rating Lowered to Hold at StockNews.com - MarketBeat

Feb 01, 2025
pulisher
Feb 01, 2025

Needham & Company LLC Issues Positive Forecast for Veracyte (NASDAQ:VCYT) Stock Price - MarketBeat

Feb 01, 2025
pulisher
Jan 31, 2025

Veracyte Stock Soars to 52-Week High, Reaching $46.12 - MSN

Jan 31, 2025
pulisher
Jan 31, 2025

Veracyte Stock Soars to 52-Week High, Reaching $46.12 By Investing.com - Investing.com Australia

Jan 31, 2025
pulisher
Jan 30, 2025

Veracyte stock price target raised to $51 at Needham - MSN

Jan 30, 2025
pulisher
Jan 29, 2025

Veracyte stock price target raised to $51 at Needham By Investing.com - Investing.com Canada

Jan 29, 2025
pulisher
Jan 29, 2025

Demystifying Veracyte: Insights From 7 Analyst Reviews - Benzinga

Jan 29, 2025
pulisher
Jan 29, 2025

Needham Boosts Price Target on Veracyte to $51 From $44, Keeps Buy Rating -January 29, 2025 at 07:55 am EST - Marketscreener.com

Jan 29, 2025
pulisher
Jan 26, 2025

Exchange Traded Concepts LLC Has $2.75 Million Stock Position in Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat

Jan 26, 2025
pulisher
Jan 25, 2025

AEGON ASSET MANAGEMENT UK Plc Sells 39,048 Shares of Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat

Jan 25, 2025
pulisher
Jan 25, 2025

Assenagon Asset Management S.A. Decreases Stake in Veracyte, Inc. (NASDAQ:VCYT) - Defense World

Jan 25, 2025
pulisher
Jan 24, 2025

Brokerages Set Veracyte, Inc. (NASDAQ:VCYT) Target Price at $41.13 - MarketBeat

Jan 24, 2025
pulisher
Jan 24, 2025

Veracyte, Inc. (NASDAQ:VCYT) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World

Jan 24, 2025
pulisher
Jan 21, 2025

Veracyte, Inc. (NASDAQ:VCYT) Shares Sold by AMI Asset Management Corp - MarketBeat

Jan 21, 2025
pulisher
Jan 21, 2025

Legal Advantage Investments Inc. Makes New $250,000 Investment in Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat

Jan 21, 2025
pulisher
Jan 19, 2025

Avanza Fonder AB Makes New $1.38 Million Investment in Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat

Jan 19, 2025
pulisher
Jan 19, 2025

StockNews.com Upgrades Veracyte (NASDAQ:VCYT) to “Buy” - Defense World

Jan 19, 2025
pulisher
Jan 18, 2025

Veracyte (NASDAQ:VCYT) Stock Rating Upgraded by StockNews.com - MarketBeat

Jan 18, 2025
pulisher
Jan 17, 2025

First Week of September 19th Options Trading For Veracyte (VCYT) - Nasdaq

Jan 17, 2025
pulisher
Jan 14, 2025

Veracyte Inc (VCYT) Shares Gap Down to $40.865 on Jan 14 - GuruFocus.com

Jan 14, 2025
pulisher
Jan 14, 2025

Cathie Wood's Ark Invest Trims Palantir Again As Peter Thiel Co-Founded Firm's Stock Tumbles Nearly 15% In 2025 - Benzinga

Jan 14, 2025
pulisher
Jan 13, 2025

JPMorgan Chase & Co. Has $11.80 Million Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT) - Defense World

Jan 13, 2025
pulisher
Jan 13, 2025

Harbor Capital Advisors Inc. Reduces Position in Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat

Jan 13, 2025
pulisher
Jan 12, 2025

Catherine Wood's Strategic Reduction in Veracyte Inc Shares - GuruFocus.com

Jan 12, 2025
pulisher
Jan 10, 2025

Diversified Trust Co Cuts Stake in Veracyte, Inc. (NASDAQ:VCYT) - MarketBeat

Jan 10, 2025
pulisher
Jan 09, 2025

Veracyte, Inc. (NASDAQ:VCYT) Has Found A Path To Profitability - Yahoo Finance

Jan 09, 2025
pulisher
Jan 08, 2025

Veracyte Gains 44% in a Year: What's Driving the Stock? - MSN

Jan 08, 2025
pulisher
Jan 07, 2025

The Zacks Rank Explained: How to Find Strong Buy Medical Stocks - Yahoo Finance

Jan 07, 2025
pulisher
Jan 06, 2025

Veracyte director Karin Eastham sells shares worth $403,005 By Investing.com - Investing.com Australia

Jan 06, 2025
pulisher
Jan 06, 2025

Insider Selling: Veracyte, Inc. (NASDAQ:VCYT) Director Sells 10,000 Shares of Stock - MarketBeat

Jan 06, 2025
pulisher
Jan 06, 2025

Veracyte director Karin Eastham sells shares worth $403,005 - Investing.com

Jan 06, 2025

Veracyte Inc Stock (VCYT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Veracyte Inc Stock (VCYT) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
EPSTEIN ROBERT S
Director
Jan 06 '25
Option Exercise
8.04
20,000
160,800
64,598
EASTHAM KARIN
Director
Jan 02 '25
Option Exercise
5.28
10,000
52,800
28,497
EASTHAM KARIN
Director
Jan 02 '25
Sale
40.30
10,000
403,006
18,497
$112.35
price down icon 8.57%
diagnostics_research LH
$244.31
price down icon 1.30%
$173.35
price down icon 0.91%
diagnostics_research WAT
$405.91
price down icon 1.25%
diagnostics_research MTD
$1,378.79
price up icon 1.58%
diagnostics_research IQV
$207.42
price down icon 1.29%
Cap:     |  Volume (24h):